GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 6, 2007, Pages

  McClean, Paula L ^a   Irwin, Nigel ^a   Cassidy, Roslyn S ^a   Holst, Jens J ^b   Gault, Victor A ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antagonist; Gastric inhibitory polypeptide; High fat feeding

Indexed keywords

(PRO 3)GIP ANTAGONIST; ADIPONECTIN; CORTICOSTERONE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; RESISTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HYPERTROPHY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LOCOMOTION; MALE; METABOLIC DISORDER; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL;

ADIPOKINES; ADIPOSE TISSUE; ANIMALS; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BODY WEIGHT; CORTICOSTERONE; DIETARY FATS; EATING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; INCRETINS; INSULIN; INSULIN RESISTANCE; LIPIDS; LIVER; MALE; MICE; MOTOR ACTIVITY; MUSCLE, SKELETAL; OBESITY; PANCREAS; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 37149047560     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00460.2007     Document Type: Article

References (52)

1. Bailey CJ, Day C, Bray GA, Lipson LG, Flatt PR. Role of adrenal glands in the development of abnormal glucose and insulin homeostasis in genetically obese (ob/ob) mice. Horm Metab Res 18: 357-360, 1986.
2. Bailey CJ, Flatt PR, Kwasowski P, Powell CJ, Marks V. Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta Endocrinol (Copenh) 112: 224-229, 1986.
3. Beltowski J. Adiponectin and resistin - new hormones of white adipose tissue. Med Sci Monit 9: RA55-RA61, 2003.
4. Creutzfeldt W, Ebert R, Willms B, Frerichs H, Brown JC. Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia 14: 15-24, 1978.
5. Ding KH, Zhong Q, Xie D, Chen HX, Della-Fera MA, Bollag RJ, Bollag WB, Gujral R, Kang B, Sridhar S, Baile C, Curl W, Isales CM. Effects of glucose-dependent insulinotropic polypeptide on behaviour. Peptides 27: 2750-2755, 2006.
6. Donckier JE. Endocrine diseases and diabetes. In: Textbook of Diabetes (3rd ed.), edited by Pickup JC and Williams G. Oxford, UK: Blackwell Science, 2003, p. 27.1-27.25.
7. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 117: 24-32, 2007.
8. Dupre J, Greenidge N, McDonald TJ, Ross SA, Rubinstein D. Inhibition of actions of glucagon in adipocytes by gastric inhibitory polypeptide. Metabolism 25: 1197-1199, 1976.
9. Eckel RH, Fujimoto WY, Brunzell JD. Gastric inhibitory polypeptide enhanced lipoprotein activity in cultured preadipocytes. Diabetes 28: 1141-1142, 1979.
10. Ehses JA, Casilla VR, Doty T, Pospisilik JA, Winter KD, Demuth HU, Pederson RA, McIntosh CH. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 144: 4433-4445, 2003.
11. Falko JM, Crockett SE, Cataland S, Mazzaferri EL. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. J Clin Endocrinol Metab 41: 260-265, 1975.
12. Flatt PR, Bailey CJ. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/) mice. Diabetologia 20: 573-577, 1981.
13. Flatt PR, Bailey CJ, Kwasowski P, Swanston-Flatt SK, Marks V. Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice. Diabetes 32: 433-435, 1983.
14. Flatt PR, Bailey CJ, Kwasowski P, Page T, Marks V. Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice. J Endocrinol 101: 249-256, 1984.
15. Flatt PR, Bailey CJ, Kwasowski P, Swanston-Flatt SK. Effects of diets rich in sucrose, coconut fat and safflowerseed oil on the development of the obese hyperglycaemic (ob/ob) syndrome in mice. Diabetes Res 13: 23-28, 1990.
16. Gault VA, O'Harte FP, Harriott P, Flatt PR. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem Biophys Res Commun 290: 1420-1426, 2002.
17. Gault VA, O'Harte FP, Flatt PR. Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential? Neuropeptides 37: 253-263, 2003.
18. 3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 54: 2436-2446, 2005.
19. Gault VA, McClean PL, Cassidy RS, Irwin N, Flatt PR. Chemical GIP receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high fat and cafeteria diets. Diabetologia 50: 1752-1762, 2007.
20. Getty-Kaushik L, Song DH, Boylan MO, Corkey BE, Wolfe MM. Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification. Obesity (Silver Spring) 14: 1124-1131, 2006.
21. Goodpaster BH, He J, Watkins S, Kelley DE. Skeletal muscle lipid content and insulin resistance: evidence for a paradox in endurance-trained athletes. J Clin Endocrinol Metab 86: 5755-5761, 2001.
22. Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gnuili D, Mari A, Nanni G, Castagneto M, Calvani M, Mingrone G. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 55: 2025-2031, 2006.
23. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino S, Drucker DJ. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117: 143-152, 2007.
24. Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202: 517-527, 2005.
25. Holscher C, Schmid S, Pilz PK, Sansig G, van der Putten H, Plappert CF. Lack of the metabotropic glutamate receptor subtype 7 selectively impairs short-term working memory but not long-term memory. Behav Brain Res 154: 473-481, 2004.
26. 3)GIP, prevents the development of diabetes and related metabolic abnormalities associated with genetically-inherited obesity in ob/ob mice. Diabetologia 50: 1532-1540, 2007.
27. Kim SJ, Nian C, McIntosh CH. Activation of lipoprotein lipase (LPL) by glucose-dependent insulinotropic polypeptide (GIP) in adipocytes: a role for a protein kinase B (PKB), LKB1 and AMP-activated protein kinase (AMPK) cascade. J Biol Chem 282: 8557-8567, 2007.
28. Knapper JM, Puddicombe SM, Morgan LM, Fletcher JM. Investigations into the actions of glucose-dependent insulinotropic polypeptide and glucagons-like peptide-1(7-36) on lipoprotein lipase activity in explants of rat tissue. J Nutr 125: 183-188, 1995.
29. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, Holst JJ, Sestoft L. Diminished gastric inhibitory polypeptide (GIP) response to a meal in newly diagnosed type I (insulin dependent) diabetics. J Clin Endocrinol Metab 56: 1306-1312, 1983.
30. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8: 738-742, 2002.
31. Oben J, Morgan L, Fletcher J, Marks V. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 130: 267-272, 1991.
32. Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539, 1994.
33. Pederson RA, Brown JC. The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas. Endocrinology 99: 780-785, 1976.
34. Ponter AA, Salter DN, Morgan LM, Flatt PR. The effect of energy source and feeding level on the hormones of the entero-insular axis and plasma glucose in the growing pig. Br J Nutr 66: 187-197, 1991.
35. Ross SA, Dupre J. Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects. Diabetes 27: 327-333, 1978.
36. Rubino F, Gagner M, Gentileschi P, Kini S, Fukuyama S, Feng J, Diamond E. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg 240: 236-242, 2004.
37. Ryysy L, Hakkinen AM, Goto T, Vehkavaara S, Westerbacka J, Halavaara J, Yki-Jarvinen. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49: 749-758, 2000.
38. Salera M, Giacomoni P, Pironi L, Cornia G, Capelli M, Marini A, Benfenati F, Miglioli M, Barbara L. Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. J Clin Endocrinol Metab 55: 329-336, 1982.
39. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 106: 171-176, 2000.
40. Simonsen L, Holst JJ, Deacon CF. Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs. Diabetologia 49: 706-712, 2006.
41. Stevens JF. Determination of glucose by an automatic analyser. Clin Chim Acta 32: 199-201, 1971.
42. Tomlinson JW, Stewart PM. Mechanisms of disease: selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for metabolic syndrome. Nat Clin Pract Endocrinol Metab 1: 92-99, 2005.
43. Trumper A, Trumper K, Horsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J Endocrinol 174: 233-246, 2002.
44. Tse TF, Clutter WE, Shah SD, Cryer PE. Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion. J Clin Invest 72: 278-286, 1983.
45. Ugleholdt R, Poulsen LH, Holst PJ, Irminger JC, Orskov C, Pedersen J, Zhu X, Steiner DF, Holst JJ. Prohomone convertase 1/3 is essential for the processing of the glucose-dependent insulinotropic polypeptide (GIP) precursor. J Biol Chem 281: 11050-11057, 2006.
46. Usdin TB, Mezey E, Button DC, Brownstein MJ, Bonner TI. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 133: 2861-2870, 1993.
47. Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88: 2706-2713, 2003.
48. Yamada Y, Miyawaki K, Tsukiyama K, Harada N, Yamada C, Seino Y. Pancreatic and extrapancreatic effects of gastric inhibitory polypeptide. Diabetes 55: S86-S91, 2006.
49. Yip RG, Boylan MO, Kieffer TJ, Wolfe MM. Functional GIP receptors are present on adipocytes. Endocrinology 139: 4004-4007, 1998.
50. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci 66: 91-103, 2000.
51. Yki-Jarvinen H. Insulin resistance in type 2 diabetes. In: Textbook of Diabetes (3rd ed.), edited by Pickup JC and Williams G. Oxford, UK: Blackwell Science, 2003, p. 22.1-22.19.
52. Zhou H, Yamada Y, Tsukiyama K, Miyawaki K, Hosokawa M, Nagashima K, Toyoda K, Naitoh R, Mizunoya W, Fushiki T, Kadowaki T, Seino Y. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action. Biochem Biophys Res Commun 335: 937-942, 2005.